НОВЫЕ ЛАБОРАТОРНЫЕ ТЕСТЫ, ОСНОВАННЫЕНА ОПРЕДЕЛЕНИИ ПРОДУКЦИИ ИНТЕРФЕРОНА ? IN VITRO,В ДИАГНОСТИКЕ ЛАТЕНТНОЙ ТУБЕРКУЛЕЗНОЙ ИНФЕКЦИИУ БОЛЬНЫХ РЕВМАТИЧЕСКИМИ ЗАБОЛЕВАНИЯМИПРИ ПЛАНИРОВАНИИ И ПРОВЕДЕНИИ ЛЕЧЕНИЯИНГИБИТОРАМИ ФАКТОРА НЕКРОЗА ОПУХОЛИ ?

1. <div><p>Насонов Е.Л. Фармакотерапия ревматоидного артрита в эру генно-инженерных биологических препаратов. Тер арх 2007;5:5-8.</p><p>Furst D.E., Keystone E.C., Kirkham B. et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2008. Ann Rheum Dis 2008;67:2-25.</p><p>Choy E.H., Panayi C.S. Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med 2001;344:907-16.</p><p>Насонов Е.Л. Применение инфликсимаба (моноклональные антитела к фактору некроза опухоли) в ревматологии: новые данные. РМЖ 2004;20:1123-7.</p><p>Tracey D., Klareskog L., Sasso E.H. et al. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol Ther 2008;117:244-79.</p><p>Keane J., Gershon S., Wise R.P. et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001;345:1098-104.</p><p>Gomez-Reino J.J., Carmona L., Valverde V.R. et al. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report. Arthr Rheum 2003;48:2122-7.</p><p>Wolfe F., Michaud K., Anderson J., Urbansky K. Tuberculosis infection in patients with rheumatoid arthritis and the effect of infliximab therapy. Arthr Rheum 2004;50:372-9.</p><p>Wallis R.S., Broder M., Wong J. et al. Reactivation of latent granulomatous infections by infliximab. Clin Infect Dis 2005;41:194-8.</p><p>Brassard P., Kezouh A., Suissa S. Antirheumatic drugs and the risk of tuberculosis. J Infect Dis 2006;43:1532-7.</p><p>Randhawa P.S. Lymphocyte subsets in granulomas of human tuberculosis: an in situ immunofluorescence study using monoclonal antibodies. Pathology 1990;22:153-5.</p><p>Gardam M.A., Keystone E.C., Menzies R. et al. Anti-tumor necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management. Lancet Infect Dis 2003;3:148-55.</p><p>Furst D.E., Wallis R., Broder M.,Beenhouwer D.O. Tumor necrosis factor antagonists: different kinetics and/or mechanisms of action may explain differences in the risk for developing granulomatous infection. Semin Arthr Rheum 2006;36:159-67.</p><p>Wallis R.S. Reactivation of latent tuberculosis by TNF blockade: the role of interferon . J Invest Dermatol Symp Proceed 2007;12:16-21.</p><p>Furst D.E., Cush J., Kaufmann S. et al. Preliminary guidelines for diagnosing and treating tuberculosis in patients with rheumatoid arthritis in immunosuppressive trials or being treated with biological agents. Ann Rheum Dis 2002;61(Suppl. 2):62-3.</p><p>Mariette X., Salmon D. French guidelines for diagnosis and treating latent and active tuberculosis in patients with RA treated with TNF blockers. Ann Rheum Dis 2003;62:791.</p><p>Carmona L., Gomez-Reino J.J.,Rodriguez-Valverde V. et al. Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists. Arthr Rheum 2005;52:1766-72.</p><p>Ledingham J., Wilkinson C., Deighton C. British Thoracic Society (BTS) recommendations for assessing risk and managing tuberculosis in patients due to start anti- TNF-{alpha} treatments. Rheumatology (Oxford) 2005; 44:1205-6.</p><p>Menzies D., Pai M., Comstock G. Metaanalysis: New tests for the diagnosis of latent tuberculosis infection: areas of uncertainty and recommendations for research. Ann Intern Med 2007;146:340-54.</p><p>Ponce de Leon D., Acevedo-Vasquez E., Sanchez-Torres A. et al. Attenuated response to purified protein derivative in patients with rheumatoid arthritis: study in a population with a high prevalence of tuberculosis. Ann Rheum Dis 2005;64:1360-1.</p><p>Nizam S., Emery P. Attenuated response to purified protein derivative in patients with rheumatoid arthritis. Ann Rheum Dis 2006;65:980.</p><p>Efthimiou P., Sood S. QuantiFERON TB Gold Test: the new standard for screening of latent tuberculosis in patients with rheumatoid arthritis? Ann Rheum Dis 2007;66:276.</p><p>Mori T., Sakatani M., Yamagishi F. et al. Specific detection of tuberculosis infection: an interferon-gamma-based assay using new antigens. Am J Respir Crit Care Med 2004;170:59-64.</p><p>Lee J.Y., Choi H.J., Park I.-N. et al. Comparison of two commercial interferon- assays for diagnosing Mycobacterium tuberculosis infection. Eur Respir J 2006;28:24-30.</p><p>Ferrara G., Losi M., D'Amico R. et al. Use in routine clinical practice of two commercial blood tests for diagnosis of infection with Mycobacterium tuberculosis: a prospective study. Lancet 2006;367:1328-34.</p><p>Kang Y.A., Lee H.W., Yoon H.I. et al. Discrepancy between the tuberculin skin test and the whole-blood interferon gamma assay for the diagnosis of latent tuberculosis infection in an intermediate tuberculosis-burden country. JAMA 2005;293:2756-61.</p><p>Harada N., Nakajima Y., Higuchi K. et al. Screening for tuberculosis infection using whole-blood interferon-gamma and Mantoux testing among Japanese healthcare workers. Infect Control Hosp Epidemiol 2006;27:442-8.</p><p>Diel R., Nienhaus A., Lange C. et al. Tuberculosis contact investigation with a new, specific blood test in a low-incidence population containing a high proportion of BCG-vaccinated persons. Respir Res 2006;7:77.</p><p>Brock I., Weldingh K., Lillebaek T. et al. Comparison of tuberculin skin test and new specific blood test in tuberculosis contacts. Am J Respir Crit Care Med 2004;170:65-9.</p><p>Porsa E., Cheng L., Seale M.M. Comparison of a new ESAT-6/CFP-10 peptide- based gamma interferon assay and a tuberculin skin test for tuberculosis screening in a moderate-risk population. Clin Vaccine Immunol 2006;13:53-8.</p><p>Liebeschuetz S., Bamber S., Ewer K. et al. Diagnosis of tuberculosis in South African children with a T-cell-based assay: a prospective cohort study. Lancet 2004;364:2196-203.</p><p>Chapman A.L., Munkanta M., Wilkinson K.A. et al. Rapid detection of active and latent tuberculosis infection in HIV-positive individuals by enumeration of Mycobacterium tuberculosis-specific T cells. AIDS 2002;16:2285-93.</p><p>Piana F., Codecasa L.R., Cavallerio P. et al. Use of a T-cell-based test for detection of tuberculosis infection among immunocompromised patients. Eur Respir J 2006;28:31-4.</p><p>Passalent L., Khan K., Richardson R. et al. Detecting latent tuberculosis infection in hemodialysis patients: a head-to-head comparison of the T-SPOT.TB test, tuberculin skin test, and an expert physician panel. Clin J Am Soc Nephrol 2007;2:68-73.</p><p>Brock I., Ruhwald M., Lundgren B. et al. Latent tuberculosis in HIV positive, diagnosed by the M. tuberculosis specific interferon- gamma test. Respir Res 2006;7:56.</p><p>Pratt A., Nicholl K., Kay L. Use of the QuantiFERON TB Gold test as part of a screening programme in patients with RA under consideration for treatment with anti- TNF-alpha agents: the Newcastle (UK) experience. Rheumatology (Oxford) 2007;46:1035-6.</p><p>Greenberg J. D., Reddy S. M., Schloss S. G. et al. Comparison of an in vitro tuberculosis interferon- assay with delayed-type hypersensitivity testing for detection of latent mycobacterium tuberculosis: a pilot study in rheumatoid arthritis. J Rheumatol 2008;35:770-5.</p><p>Vassilopoulos D., Stamoulis N., Hadziyannis E., Archimandritis A.J. Usefulness of enzyme-linked immunospot assay (Elispot) compared to tuberculin skin testing for latent tuberculosis screening in rheumatic patients scheduled for anti-tumor necrosis factor treatment. J Rheumatol 2008;35:1271-6.</p><p>Chen D.-Y., Shen G.-H., Hsieh T.-Y. et al. Effectiveness of the combination of a whole-blood interferon-gamma assay and the tuberculin skin test in detecting latent tuberculosis infection in rheumatoid arthritis patients receiving adalimumab therapy. Arthr Rheum 2008;59:800-6.</p><p>Matulis G., Jь ni P., Villiger P. M.,Gadola S. D. Detection of latent tuberculosis in immunosuppressed patients with autoimmune diseases: performance of a Mycobacterium tuberculosis antigen-specific interferon assay. Ann Rheum Dis 2008;67:84-90.</p><p>Park J.H., Seo G.Y., Lee J.S. et al. Positive conversion of tuberculin skin test and performance of interferon release assay to detect hidden tuberculosis infection during anti-tumor necrosis factor agent trial. J Rheumatol 2009;36:2158-63.</p><p>Sellam J., Hamdi H., Roy C. et al. Comparison of in vitro-specific blood tests with tuberculin skin test for diagnosis of latent tuberculosis before anti-TNF therapy. Ann Rheum Dis 2007;66:1610-5.</p><p>Hamdi H., Mariette X., Godot V. et al. Inhibition of anti-tuberculosis T-lymphocyte function with tumour necrosis factor antagonists. Arthr Res Ther 2006;8:114.</p><p>Hatemi G., Melikoglu M., Fresko I. et al. Infliximab does not suppress the tuberculin skin test (purified protein derivative). J Rheumatol 2007;34:474-80.</p></div><br />